Glaucoma Debate Club 2022: Cases in Sustained IOP Control (CME Monograph)

Activity Description and Purpose

The successful treatment of glaucoma is challenged by many factors, including patient nonadherence to topical therapies, waning efficacy of topical therapies as disease progresses, and risks associated with traditional glaucoma surgery. As a result, several new approaches for managing glaucoma have been introduced that can help address some of the challenges posed by traditional medical therapy. These include sustained drug-eluting devices and minimally invasive surgical procedures. The choice of intervention is not straightforward, and a nuanced, patient-centered approach to selection is needed. In this educational activity, experts explore different treatment options for various patient scenarios through cases in a debate-style format. The desired result of this educational activity is to enable glaucoma specialists and other ophthalmologists to confidently incorporate a variety of new treatments beyond topical drugs to improve visual outcomes for patients with glaucoma.

Target Audience

This educational activity is intended for glaucoma specialists and other ophthalmologists caring for patients with glaucoma.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review safety and efficacy data for approved and emerging sustained-release drug delivery devices for glaucoma
  • Identify patients with glaucoma who are most likely to benefit from sustained-release drug delivery treatment
  • Choose appropriate MIGS procedures for a variety of patient scenarios
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/01/2022
Course expires: 
08/31/2023
Cost:
$0.00

Faculty

Iqbal Ike K. Ahmed, MD, FRCSC (Co-Chair)
Professor
Department of Ophthalmology and Visual Sciences
University of Utah
Salt Lake City, Utah
Director, Alan S. Crandall Center for Glaucoma Innovation
John A. Moran Eye Center
Director, Glaucoma & Advanced Anterior Segment Surgery (GAASS) Fellowship
Research Director, Kensington Eye Institute
University of Toronto
Toronto, Canada
Division Head, Ophthalmology
Trillium Health Partners
Mississauga, Canada
Chief Innovation Officer
Prism Eye Institute
Oakville, Canada
Thomas W. Samuelson, MD (Co-Chair)
Founding Partner and Attending Surgeon
Glaucoma and Anterior Segment Surgery
Minnesota Eye Consultants
Adjunct Professor
University of Minnesota
Minneapolis, Minnesota
Marlene R. Moster, MD
Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Attending Surgeon, Glaucoma Service
Wills Eye Institute
Philadelphia, Pennsylvania
Arsham Sheybani, MD
Assistant Professor of Ophthalmology
Fellowship Director, Glaucoma and Anterior Segment Surgery
Residency Program Director, Ophthalmology
Washington University School of Medicine
St Louis, Missouri

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Iqbal Ike K. Ahmed, MD, is a consultant for Aequus BioPharma, Inc, Aerie Pharmaceuticals, Inc, Akorn, Inc, Alcon, Allergan, Aquea Health, Inc, ArcScan, Inc, Avisi, Bausch & Lomb Incorporated, Beaver-Visitec International, Beyeonics Surgical Ltd, Bionode, Carl Zeiss Meditec, Inc, CorNeat Vision Ltd, Elios Vision, ElutiMed, Equinox, Genentech, Inc, Glaukos Corporation, Heine, Heru, Iantrek, iCare, Injectsense, Inc, IRIDEX Corporation, iSTAR, Ivantis Inc, Johnson & Johnson Vision Care, Inc, LayerBio, Inc, MicroOptx, MicroSurgical Technology, Myra Vision, New World Medical, Inc, Ocular Instruments, Ocular Therapeutix, Inc, Omega Ophthalmics, Polyactiva Pty Ltd, Radiance Therapeutics, Inc, Ripple Therapeutics, Sanoculis Ltd, Santen Inc, Shifamed, LLC, Sight Sciences, Smartlens, Inc, Strõma Medical Corporation, Thea Pharmaceuticals Limited, Vialase, Inc, Vizzario, and W. L. Gore & Associates, Inc; is on the speakers bureau for Alcon, Allergan, Carl Zeiss Meditec, Inc, Heine, Johnson & Johnson Vision Care, Inc, and MicroSurgical Technology; and is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bionode, Glaukos Corporation, iCare, Ivantis Inc, Johnson & Johnson Vision Care, Inc, New World Medical, Inc, and Santen Inc.

Marlene R. Moster, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, and Qura; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, and Bausch & Lomb Incorporated; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, InnFocus, Inc, and New World Medical, Inc; and has individual stocks or stock options in Qura.

Thomas W. Samuelson, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Belkin Vision, ELT Sight, Equinox, Glaukos Corporation, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Johnson & Johnson Vision Care, Inc, MicroOptx, New World Medical, Inc, Ocuphire Pharma, Polyactiva Pty Ltd, Ripple Therapeutics, Santen Inc, Sight Sciences, TearClear, Valeant, ViaLase, Inc, and Zeiss; and has individual stocks or stock options in Belkin Vision, Equinox, Ivantis Inc, Ocuphire Pharma, Sight Sciences, TearClear, and ViaLase, Inc.

Arsham Sheybani, MD, is a consultant for AbbVie Inc, Alcon, Glaukos Corporation, Ivantis Inc, and Santen Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Tony Realini, MD, is a consultant for Belkin Laser, iStar Medical, Ivantis Inc, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from AbbVie Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, AbbVie Inc, EyeNet, or the American Academy of Ophthalmology.

©2022 MedEdicus LLC. 265.2

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Clicking Take course indicates that you have reviewed the CME information for this activity.